Pretreatment Evaluation on Non-Small-cell Lung Cancer

ATS Board of Directors, March 1997 and by the ERS Executive Committee , April 1997

Source: Guideline 1997

Number: 1998

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
ATS Board of Directors, March 1997 and by the ERS Executive Committee , April 1997. Pretreatment Evaluation on Non-Small-cell Lung Cancer. Guideline 1997

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Lung Micobiome in Lung Cancer Source: Virtual Congress 2020 – Biological mechanisms of lung cancer Year: 2020
Effect of the Liverpool Healthy Lung Programme on Outcomes in Lung Cancer Source: Virtual Congress 2020 – Screening and early lung cancer Year: 2020
The Role Of TGF-ß in Lung Cancer Development in COPD Patients Source: Virtual Congress 2020 – Biological mechanisms of lung cancer Year: 2020
Lung Microbiota and Streptococcal enrichment in Central Lung Cancer Source: Virtual Congress 2020 – Biological mechanisms of lung cancer Year: 2020
The Burden of Asymptomatic Lung Cancer Source: International Congress 2019 – Early detection, follow-up and epidemiology of lung cancer Year: 2019
Lung Cancer vs. „Young Cancer“ – Is There a Difference? Source: Virtual Congress 2021 – COVID-19 and management of lung cancer Year: 2021
Intratumoral Hyperthermic Chemotherapy Injection in Peripheral Non-Small Cell Lung Cancer; a Pilot Study. Source: Virtual Congress 2020 – Novelties in interventional pulmonology: expanding horizons Year: 2020
Resected Non-Small Cell Lung Cancer : A 5-year Experience Source: Virtual Congress 2020 – Localised non-small cell lung cancer Year: 2020
Characterization of Patients with KRAS-Mutated Advanced Non-Small Cell Lung Cancer Source: International Congress 2019 – Thoracic oncology: Treatment, diagnostic options and biology Year: 2019
Clinical Features and Treatment Outcome of Carcinomatous Pericarditis due to Lung Cancer. Source: International Congress 2018 – Lung cancer: modern therapies and beyond Year: 2018
Determinants of Respiratory Muscle Strength in Lung Cancer Source: International Congress 2019 – New views on testing and training of respiratory muscles Year: 2019
Short Term Multidisciplinary Pulmonary Rehabilitation Is Effective In Early Stage Non Small Cell Lung Cancer Source: Virtual Congress 2020 – Screening and early lung cancer Year: 2020
Consequences of Lung Cancer: Mortality and Comorbidity in Danish Patients with Lung Cancer 1998-2010 Source: International Congress 2019 – Symptoms, risks, complications and palliative care in thoracic oncology Year: 2019
Increase in hospital admissions in smokers with Interstitial Lung Abnormalities in the Danish Lung Cancer Screening Trial (DLCST) Source: International Congress 2018 – COPD and chronic respiratory disease: from misclassification to radiological findings Year: 2018
Pathology of Vaping-Associated Lung Injury Source: Virtual Congress 2020 – E-cigarette or Vaping, product use Associated Lung Injury (EVALI) Year: 2020
NRG1 Fusion-Positive Lung Cancers: Clinicopathologic Profile and Treatment Outcomes from a Global Multicenter Registry Source: International Congress 2019 – Biology of lung cancer Year: 2019
Cancer Source: Eur Respir Monogr 2016; 71: 151-159 Year: 2016
Lung Cancer and bronchial infection Source: International Congress 2017 – Respiratory infections in critically ill and immuno-depressed patientes Year: 2017
Impact of Emphysema Heterogeneity on Lung Function after Bronchoscopic Lung Volume Reduction Source: International Congress 2019 – Interventional pulmonology: re-sculpting the airway Year: 2019